Disease-associated antigen

The term 'Disease-associated antigen' is a broad, categorical descriptor for any molecule—typically a protein, glycoprotein, or glycolipid—that is uniquely expressed or significantly upregulated in a diseased state. In oncology, these are generally classified as tumor-associated antigens (TAAs), which are expressed in normal tissues but overexpressed in tumors, or tumor-specific antigens (TSAs), which are entirely unique to malignant cells due to mutations or viral integration (Source: Abbas et al., 'Cellular and Molecular Immunology'). These antigens serve as the primary targets for various immunotherapeutic modalities, including monoclonal antibodies, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies (Source: National Cancer Institute). Beyond oncology, disease-associated antigens can include viral or bacterial proteins in infectious diseases and modified self-proteins in autoimmune conditions (Source: Nature Reviews Rheumatology). Because this term describes a diverse class of molecules rather than a single protein, it does not have a unique molecular structure or a single conserved biological pathway. The therapeutic utility of any specific disease-associated antigen is defined by its differential expression profile, which determines the clinical risk of 'on-target, off-tumor' toxicity in healthy tissues (Source: Nature Reviews Cancer).

Other names

Tumor-associated antigen (TAA)Tumor-specific antigen (TSA)NeoantigenOncofetal antigenAutoantigen

Varies significantly depending on the specific antigen; common mechanisms include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct inhibition of oncogenic signaling pathways.